Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Intraperitoneal Paclitaxel Clear all

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Interventions: HIPEC, Carboplatin, Paclitaxel; Procedure · Drug
Lead sponsor: Andrea Jewell; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
Interventions: Paclitaxel, Cisplatin IP; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Metastatic Appendiceal Adenocarcinoma, Intraperitoneal Paclitaxel
Interventions: Dexamethasone, Diphenhydramine, Famotidine, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: adjuvant therapy, paclitaxel, carboplatin, bevacizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 17
States / cities: Orange, California • Chicago, Illinois • Iowa City, Iowa + 9 more

Conditions: Ovarian Cancer, Primary PERITONEUM, Fallopian Tube Cancer
Interventions: Paclitaxel,Cisplatin, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Peritoneal Neoplasms
Interventions: nanoparticulate paclitaxel; Drug
Lead sponsor: CritiTech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Kansas City, Kansas • Wichita, Kansas • Oklahoma City, Oklahoma

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Paclitaxel, Carboplatin, Avastin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more

Conditions: Diseases of Oesophagus Stomach and Duodenum
Interventions: Dexamethasone, Diphenhydramine, Famotidine, Mitomycin C, Cisplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: chemotherapy, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 21 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 5
States / cities: Orange, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Ovarian Carcinoma
Interventions: docetaxel; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 19 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Uterine Carcinoma
Interventions: Paclitaxel/Carboplatin, Pelvic radiation therapy; Drug · Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
Interventions: Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Hyperthermic Intraperitoneal Chemotherapy, Laparoscopy, Lymphadenectomy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Surgical Procedure; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ovarian Carcinoma, Stage 3 or 4, Epithelial Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: Paclitaxel, N-acetylcysteine, Cisplatin; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 75 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Ovarian Carcinoma
Interventions: NanoPac® 100 mg/m2, NanoPac® 200 mg/m2, NanoPac® 300 mg/m2, NanoPac® 400 mg/m2, Standard of Care Intravenous Chemotherapy; Drug
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 4 more

Conditions: Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel Adenocarcinoma, Hepatobiliary Carcinoma in Situ
Interventions: Paclitaxel Q2W, Paclitaxcel Q3W; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: Gastric Cancer, Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma
Interventions: Paclitaxel, Leucovorin, Fluorouracil; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, cisplatin, paclitaxel; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: Springfield, Missouri • Oklahoma City, Oklahoma • Providence, Rhode Island + 2 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
Interventions: Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: David O'Malley; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Hilliard, Ohio

Conditions: Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal Adenocarcinoma
Interventions: Ivonescimab, IP PTX; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions: Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis; Drug · Radiation · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
Interventions: Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: Paclitaxel, NALIRIFOX; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

A Phase I Study of Intraperitoneal Hyperthermic Docetaxel

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis